The Experts in Animal Health

printer friendly version

Brakke Consulting’s
Animal Health News & Notes for April 8, 2011

Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon, DVM MBA
Brakke news
Pain Management report
earnings news
Boehringer Ingelheim Vetmedica
Digital Angel
other news
Du Pont
Entest BioMedical

Pain management is one of the leading topics in veterinary medicine today.  The products represent a substantial market segment with potential still to be tapped. 
Brakke Consulting’s annual report on Pain Management Products for Dogs and Cats includes such valuable information as:
  – overview of acute and chronic pain in small animals
  – review of current products
  – estimates of US sales and prices of leading products
  – pain management products in development
  – review of nutritional supplements used for chronic pain
  – review of therapeutic diets for joint care
  – 2011 survey of over 200 small animal veterinarians regarding use of pain management products
Pain Management Products for Dogs and Cats 2011 can be purchased for $5,500. Questions about the study can be answered by project manager Lynn Fondon, DVM, MBA at 972-243-4033, or email
> Boehringer Ingelheim reported results for the full year 2010.  The Animal Health business reported net sales of EUR 921 million ($1,220 million), an increase of 51%. This massive increase is attributable on the one hand to organic growth, particularly the swine vaccine INGELVAC CircoFLEX, and on the other hand to the acquisition of parts of animal health business of Pfizer/Fort Dodge at the end of 2009. (company website)
> Digital Angel reported results for 2010.  Animal ID Segment revenues for the year were $30.8 million, unchanged from 2009.  (company website)
> The European Commission has approved the proposed sale of Dansico A/S to E.I. du Pont de Nemours and Company.  The sale, valued at $6.4 billion, still needs to win the approval of Danisco’s shareholders to be completed. (Feedstuffs) 
> Entest BioMedical Inc. announced a collaboration with RenovoCyte LLC and Medistem Inc. to test a stem cell therapy for treating hip dysplasia in dogs.  Entest said it will employ Medistem’s Canine Endometrial Regenerative Cells and RenovoCyte’s investigational protocols at one of the company’s animal hospitals. (Veterinary Practice News)
> EU  Virbac announced that the European Commission has awarded the company a European registration for CaniLeish, the first vaccine against canine leishmaniosis in Europe. CaniLeish will initially be launched in Portugal at the end of the first half of 2011; this will be followed by launches in other countries in the endemic area of southern Europe. (company press release) 
AAHA/OVMA Conference
March 24-27, 2011
The AAHA/OVMA Conference—Toronto 2011 had a total of 5,596 attendees, including nearly 2,000 veterinarians, 292 practice managers, and 1,449 exhibitor personnel.
> US – EQUINE HERPESVIRUS   The New York State College of Veterinary Medicine at Cornell University has voluntarily quarantined its equine hospital after two cases of the highly contagious neurologic form of equine herpesvirus (EHV-1) were confirmed there in late March. (Animal Pharm)
> BULGARIA – FMD  Bulgarian veterinary authorities are culling 350 domestic animals after detecting a new outbreak of foot-and-month disease (FMD) in a remote village near the Turkish border. The FMD outbreak is Bulgaria’s sixth this year. (Animal Pharm)
> US – MEAT INSPECTION   USDA has proposed a mandatory “test and hold” rule for meat processors, which would require meat processors to hold off shipping beef, pork and poultry until testing indicates the product is free of E. coli and other illness-causing pathogens. Most US meat processors have already been using a test-and-hold system for several years. (Cattle Network)
> CANADA – ALLERGY RESEARCH   Researchers at McMaster University in Canada are developing a vaccine that provides long-term protection against the symptoms of allergies to cats in humans.  Early trials suggest ToleroMune Cat is safe, effective and lasts longer than current treatments. Researchers are working with Adiga Life Sciences and the British biotech firm Circassia to develop the vaccine.  (
Based on the lack of news it appears that everyone is taking some time off after pushing to finish the first quarter on or over budget.  Early verbal reports are that we’ll see some fairly good revenue numbers for the first quarter. We are looking forward to the final quarterly reports to confirm. 
Probably some of the biggest news this week is in the feed grain markets. Corn futures this past Monday reached $8.00 per bushel for a period.  It appears that Brakke Consulting predictions in January that we’d see $7/bushel corn, $4.00/gallon gasoline and increasing food prices are here in spades.  The good news is that finished beef and pork are selling at record highs so there should be no excuses from the producers on the cost of animal health products. 
As I’m writing this newsletter, it appears that we might be only hours away from a government shutdown.  No matter what happens, hopefully this political impasse will not be another excuse for the regulatory agencies to slow down the approval process. I’m not sure it can be slowed down much more, but sometimes government agencies are capable of surprises.  An interesting time!! 
Have a great weekend!!
Ron Brakke

This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at
Brakke Consulting, Inc.
2735 Villa Creek, Suite 140
Dallas, TX  75234    USA

en_USEnglish (United States)